Cyclophosphamide Treatment Options in Cleveland, OH (Updated 7/25)

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

NCT06647953

Recruiting

This phase III trial tests how well surgery plus chemotherapy compared to surgery alone works in treating patients with type I pleuropulmonary blastoma (PPB), and tests how well surgery plus standard chemotherapy with the addition of topotecan works compared to surgery plus standard chemotherapy alone in treating patients with type II and III PPB. Historically, most children with type I PPB had surgery and approximately 40% of children with type I PPB received chemotherapy following their surge... Read More

This phase III trial tests how well surgery plus chemotherapy compared to surgery alone works in treating patients with type I pleuropulmonary blastoma (PPB), and tests how well surgery plus standard chemotherapy with the addition of topotecan works compared to surgery plus standard chemotherapy alone in treating patients with type II and III PPB. Historically, most children with type I PPB had surgery and approximately 40% of children with type I PPB received chemotherapy following their surgery, usually for 22-42 weeks. There has not been a consistent standard for which children with type I PPB receive chemotherapy after surgery. For patients whose tumor has been removed completely with surgery, observation without chemotherapy may work as well as giving chemotherapy after surgery in preventing a return of the PPB tumor. The standard chemotherapy for patients with types II or III PPB in the United States is four cycles of IVADo (ifosfamide, vincristine, dactinomycin, and doxorubicin) followed by 8 cycles of IVA (ifosfamide, vincristine and dactinomycin). Ifosfamide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of tumor cells in the body. Vincristine is in a class of medications called vinca alkaloids. It works by stopping tumor cells from growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. Topotecan is in a class of medications called topoisomerase I inhibitors. It works by interfering with tumor cell DNA which kills them. Giving topotecan in addition to standard IVADo and IVA chemotherapy regimens may shrink the cancer as well as or better than the standard therapy or could decrease the chance the tumor spreads while causing fewer side effects. Read Less

Gender:

ALL

Ages:

21 years and below

Trial Updated:

07/10/2025

Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio +3 locations

Conditions: Pleuropulmonary Blastoma

Register for Updates

Learn More ›

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

NCT05382338

Recruiting

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk medulloblastoma typically have a lower chance of the cancer coming back than subjects with average-risk medulloblastoma. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effect... Read More

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk medulloblastoma typically have a lower chance of the cancer coming back than subjects with average-risk medulloblastoma. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effective at treating the cancer, there are still concerns about the side effects of such treatment. Side effects or unintended health conditions that arise due to treatment include learning difficulties, hearing loss or other issues in performing daily activities. Standard therapy for newly diagnosed average-risk or low-risk medulloblastoma includes surgery, radiation therapy, and chemotherapy (including cisplatin). Cisplatin may cause hearing loss as a side effect. In the average-risk medulloblastoma patients, this trial tests whether the addition of sodium thiosulfate (STS) to standard of care chemotherapy and radiation therapy reduces hearing loss. Previous studies with STS have shown that it may help reduce or prevent hearing loss caused by cisplatin. In the low-risk medulloblastoma patients, the study tests whether a less intense therapy (reduced radiation) can provide the same benefits as the more intense therapy. The less intense therapy may cause fewer side effects. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. The overall goals of this study are to see if giving STS along with standard treatment (radiation therapy and chemotherapy) will reduce hearing loss in medulloblastoma patients and to compare the overall outcome of patients with medulloblastoma treated with STS to patients treated without STS on a previous study in order to make sure that survival and recurrence of tumor is not worsened. Read Less

Gender:

ALL

Ages:

Between 4 years and 21 years

Trial Updated:

07/10/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +5 locations

Conditions: Childhood Medulloblastoma

Register for Updates

Learn More ›

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

NCT02176967

Active Not Recruiting

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk n... Read More

Gender:

ALL

Ages:

18 months and below

Trial Updated:

07/10/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +6 locations

Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma

Register for Updates

Learn More ›

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085

Recruiting

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin.... Read More

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy. Read Less

Gender:

ALL

Ages:

Between 1 year and 25 years

Trial Updated:

07/09/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +6 locations

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia

Register for Updates

Learn More ›

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

NCT04322318

Recruiting

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth... Read More

Gender:

ALL

Ages:

30 years and below

Trial Updated:

07/09/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +6 locations

Conditions: Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor

Register for Updates

Learn More ›

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

NCT02981628

Recruiting

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.

Gender:

ALL

Ages:

Between 1 year and 21 years

Trial Updated:

07/09/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +5 locations

Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma

Register for Updates

Learn More ›

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

NCT05304585

Recruiting

Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of the study it to find out how well patients with low risk rhabdomyosarcoma (LR-... Read More

Gender:

ALL

Ages:

21 years and below

Trial Updated:

07/09/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +6 locations

Conditions: Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma

Register for Updates

Learn More ›

Treatment of Moderate to Severe Refractory Crohn's Disease

NCT06721962

Recruiting

This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/08/2025

Locations: Cleveland Clinic, Cleveland, Ohio

Conditions: Crohns Disease

Register for Updates

Learn More ›

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

NCT04732845

Active Not Recruiting

The purpose of this study is to determine if it is possible to treat relapsed or refractory lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) with a new type of T cell-based immunotherapy (therapy that uses the immune system to treat the cancer).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/02/2025

Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio

Conditions: Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia

Register for Updates

Learn More ›

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

NCT01275677

Completed

This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies,... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/25/2025

Locations: Summa Health System - Akron Campus, Akron, Ohio +97 locations

Summa Health System - Akron Campus, Akron, Ohio

Summa Health System - Barberton Campus, Barberton, Ohio

Cleveland Clinic Cancer Center Beachwood, Beachwood, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Mary Rutan Hospital, Bellefontaine, Ohio

Strecker Cancer Center-Belpre, Belpre, Ohio

Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio

Aultman Health Foundation, Canton, Ohio

Miami Valley Hospital South, Centerville, Ohio

Geauga Hospital, Chardon, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio

Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio

The Christ Hospital, Cincinnati, Ohio

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Oncology Hematology Care Inc-Anderson, Cincinnati, Ohio

Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio

TriHealth Cancer Institute-Westside, Cincinnati, Ohio

TriHealth Cancer Institute-Anderson, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

North Coast Cancer Care-Clyde, Clyde, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Mount Carmel East Hospital, Columbus, Ohio

Columbus Oncology and Hematology Associates Inc, Columbus, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Columbus NCI Community Oncology Research Program, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

The Mark H Zangmeister Center, Columbus, Ohio

Mount Carmel Health Center West, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Grandview Hospital, Dayton, Ohio

Good Samaritan Hospital - Dayton, Dayton, Ohio

Miami Valley Hospital, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Dayton NCI Community Oncology Research Program, Dayton, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Delaware Radiation Oncology, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Hematology Oncology Center Incorporated, Elyria, Ohio

Mercy Cancer Center-Elyria, Elyria, Ohio

Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio

Blanchard Valley Hospital, Findlay, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Wayne Hospital, Greenville, Ohio

Cleveland Clinic Cancer Center Independence, Independence, Ohio

Kettering Medical Center, Kettering, Ohio

Fairfield Medical Center, Lancaster, Ohio

Lancaster Radiation Oncology, Lancaster, Ohio

Saint Rita's Medical Center, Lima, Ohio

Lima Memorial Hospital, Lima, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio

Marietta Memorial Hospital, Marietta, Ohio

Saint Luke's Hospital, Maumee, Ohio

Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio

Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio

Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Landerbrook Health Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio

Knox Community Hospital, Mount Vernon, Ohio

Licking Memorial Hospital, Newark, Ohio

Newark Radiation Oncology, Newark, Ohio

Fisher-Titus Medical Center, Norwalk, Ohio

Saint Charles Hospital, Oregon, Ohio

Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio

Southern Ohio Medical Center, Portsmouth, Ohio

North Coast Cancer Care, Sandusky, Ohio

UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio

Springfield Regional Medical Center, Springfield, Ohio

Trinity's Tony Teramana Cancer Center, Steubenville, Ohio

Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio

ProMedica Flower Hospital, Sylvania, Ohio

Mercy Hospital of Tiffin, Tiffin, Ohio

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio

Mercy Health - Saint Vincent Hospital, Toledo, Ohio

University of Toledo, Toledo, Ohio

Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio

Mercy Health - Saint Anne Hospital, Toledo, Ohio

Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio

Upper Valley Medical Center, Troy, Ohio

University Hospitals Sharon Health Center, Wadsworth, Ohio

South Pointe Hospital, Warrensville Heights, Ohio

Fulton County Health Center, Wauseon, Ohio

University of Cincinnati Cancer Center-West Chester, West Chester, Ohio

Saint Ann's Hospital, Westerville, Ohio

UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio

Clinton Memorial Hospital/Foster J Boyd Regional Cancer Center, Wilmington, Ohio

Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio

Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio

Greene Memorial Hospital, Xenia, Ohio

Genesis Healthcare System Cancer Care Center, Zanesville, Ohio

Conditions: HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7

Register for Updates

Learn More ›

Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

NCT04789408

Terminated

The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: Cleveland Clinic, Cleveland, Ohio +1 locations

Conditions: Acute Myeloid Leukemia

Register for Updates

Learn More ›

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

NCT03274492

Active Not Recruiting

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

06/24/2025

Locations: Oncology/Hematology Care Clinical Trials LLC, Cincinnati, Ohio +2 locations

Conditions: Diffuse Large B-Cell Lymphoma

Register for Updates

Learn More ›

Cyclophosphamide Treatment Options in Cleveland, OH

Match to Clinical Trials

Browse Cyclophosphamide Treatment Options in Other Ohio Cities